Related Experiment Video
Updated: Jun 27, 2026
08:48
Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models
Published on: June 30, 2023
Mitochondrial approaches for neuroprotection
Rajnish K Chaturvedi1, M Flint Beal
1Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY 10065, USA.
Annals of the New York Academy of Sciences
|December 17, 2008
Summary
Mitochondrial dysfunction is a common cause of neurodegenerative diseases. Therapies targeting this dysfunction, including supplements and antioxidants, show promise for treating conditions like Parkinson
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Mitochondrial dysfunction is a common pathological mechanism in neurodegenerative diseases.
- Mechanisms include oxidative stress, mitochondrial DNA damage, and protein interactions.
- Targeting mitochondrial dysfunction offers therapeutic potential for neurodegenerative disorders.
Purpose of the Study:
- To review the therapeutic efficacy of agents targeting mitochondrial dysfunction.
- To discuss the current status of clinical trials for these agents.
- To explore novel therapeutic targets for neurodegenerative diseases.
Main Methods:
- Review of in vitro and animal model studies.
- Analysis of clinical trial data for specific compounds.
- Discussion of emerging therapeutic targets.
Main Results:
- Creatine, coenzyme Q10, idebenone, MitoQ, and SS-31 show potential in preclinical models.
- Clinical trials for some agents are ongoing or completed.
- Peroxisome proliferator-activated receptor-gamma-coactivator and sirtuins are identified as promising targets.
Conclusions:
- Therapeutic strategies targeting mitochondrial dysfunction are promising for neurodegenerative diseases.
- Further research and clinical trials are needed to validate efficacy.
- Novel targets offer future avenues for therapeutic development.
